Takeda suffers OTC decline
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Takeda reported Consumer Healthcare sales down by 4.9% to ¥79.0 billion (€614 million) in its financial year ended 31 March 2018, reflecting the loss of the rights to distribute Taisho’s Biofermin OTC products in Japan.